HC Wainwright & Co. maintains LENZ Therapeutics at Buy, lowers price target to $16 from $38

What happened

HC Wainwright & Co. maintained its Buy rating on LENZ Therapeutics but lowered its price target to $16 from $38, a 57.9% decrease. The new target implies 358.5% upside from the October 29 closing price of $3.49.

Confirmed

Global impact / market context

A lower price target means the analyst expects less future gain than before, even while keeping a Buy rating, which tells investors the analyst still sees upside but a smaller one, so expectations for the stock's potential return are being reduced without a full downgrade.

Analyst inference

The target was cut by more than half while the rating stayed positive, so the signal is mixed rather than a full downgrade; LENZ Therapeutics shareholders must weigh weaker expected upside against the analyst's continued Buy view when deciding how to position.

Analyst inference

What to watch

1. HC Wainwright lowered its LENZ Therapeutics price target to $16 from $38, which is a 57.9% decrease, while maintaining its Buy rating on the stock. Confirmed
2. Watch whether other analysts also reduce their LENZ Therapeutics price targets or ratings, which would show whether the cut reflects a broader change in how analysts value the company's future revenue prospects. Proposed
3. Track LENZ Therapeutics shares around the $3.49 October 29 close, because the $16 target's implied 358.5% upside is measured from that price, and a different starting price changes the implied return investors actually capture. Analyst inference

Evidence

• Original source link unavailable